AE Wealth Management LLC reduced its position in shares of GlaxoSmithKline plc (NYSE:GSK) by 20.7% during the 4th quarter, HoldingsChannel reports. The fund owned 23,939 shares of the pharmaceutical company’s stock after selling 6,254 shares during the quarter. AE Wealth Management LLC’s holdings in GlaxoSmithKline were worth $849,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Field & Main Bank acquired a new position in shares of GlaxoSmithKline in the fourth quarter valued at about $132,000. Wealthcare Advisory Partners LLC lifted its holdings in shares of GlaxoSmithKline by 1,982.8% in the third quarter. Wealthcare Advisory Partners LLC now owns 3,520 shares of the pharmaceutical company’s stock worth $143,000 after acquiring an additional 3,351 shares during the last quarter. Advisory Services Network LLC lifted its holdings in shares of GlaxoSmithKline by 24.2% in the second quarter. Advisory Services Network LLC now owns 4,047 shares of the pharmaceutical company’s stock worth $175,000 after acquiring an additional 788 shares during the last quarter. Waldron LP bought a new position in shares of GlaxoSmithKline in the third quarter worth about $203,000. Finally, Belpointe Asset Management LLC bought a new position in shares of GlaxoSmithKline in the third quarter worth about $204,000. 9.66% of the stock is currently owned by hedge funds and other institutional investors.
GlaxoSmithKline plc (NYSE:GSK) opened at $36.49 on Friday. The stock has a market cap of $90,520.00, a P/E ratio of 41.94, a P/E/G ratio of 2.31 and a beta of 0.98. GlaxoSmithKline plc has a fifty-two week low of $34.52 and a fifty-two week high of $44.53. The company has a quick ratio of 0.44, a current ratio of 0.64 and a debt-to-equity ratio of 2.96.
The company also recently declared a quarterly dividend, which will be paid on Thursday, April 12th. Shareholders of record on Friday, February 23rd will be issued a dividend of $0.633 per share. This is a positive change from GlaxoSmithKline’s previous quarterly dividend of $0.50. The ex-dividend date is Thursday, February 22nd. This represents a $2.53 annualized dividend and a yield of 6.94%. GlaxoSmithKline’s dividend payout ratio (DPR) is presently 234.48%.
GSK has been the subject of a number of research reports. Kepler Capital Markets raised shares of GlaxoSmithKline from a “reduce” rating to a “hold” rating in a report on Friday. JPMorgan Chase & Co. reissued a “neutral” rating on shares of GlaxoSmithKline in a report on Tuesday, October 24th. Zacks Investment Research cut shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a report on Wednesday, January 10th. Investec lowered shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a report on Monday, November 6th. Finally, TheStreet upgraded shares of GlaxoSmithKline from a “c+” rating to a “b” rating in a report on Wednesday, October 25th. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and six have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $38.57.
ILLEGAL ACTIVITY WARNING: “AE Wealth Management LLC Has $849,000 Holdings in GlaxoSmithKline plc (GSK)” was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this article on another domain, it was illegally copied and republished in violation of U.S. & international copyright laws. The legal version of this article can be accessed at https://sportsperspectives.com/2018/02/10/ae-wealth-management-llc-has-849000-holdings-in-glaxosmithkline-plc-gsk.html.
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.